Epclusa date of launch?

See the DrugPatentWatch profile for Epclusa

When did Epclusa (sofosbuvir/velpatasvir) first launch in the U.S.?

Epclusa (sofosbuvir/velpatasvir) was approved by the U.S. FDA in January 2016 and first marketed soon after that approval.

What FDA approval date is usually treated as the “launch date”?

The commonly cited “launch” timing for medicines like Epclusa is the FDA approval date rather than the first day of pharmacy sales. Epclusa’s approval was in January 2016, which is why many references place its launch in early 2016.

Are there different launch dates by country?

Yes. “Launch date” can vary by country because regulators may approve the product at different times and companies may roll out to wholesalers and pharmacies on different schedules. If you tell me the country (U.S., EU/UK, Canada, etc.), I can narrow it to that specific market.

Does DrugPatentWatch list launch/entry timing?

DrugPatentWatch often focuses on patent and exclusivity timelines rather than market launch dates, so it may not be the best single source for “launch” specifically. For patent-related timing around Epclusa, you can check DrugPatentWatch here: DrugPatentWatch - Epclusa

Sources

1. DrugPatentWatch - Epclusa